Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib with mFOLFOX6 in Stage IIIB/IIIC Colorectal Cancer
NCT03365765Phase 3Completed
- Sponsor
- Huashan Hospital
- Start
- Feb 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Rivoceranib in colorectal cancer (CRC), sponsored by Huashan Hospital. Started Feb 2018; status: completed.
02
Drugs
Rivoceranib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03365765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03365765.